Hematologic complications of rheumatic disease therapies.
Hematologic side effects of rheumatic disease therapies are generally mild and reversible; however, the clinician must be alert for potential profound and life-threatening toxicities. A knowledge of the toxicity patterns for the individual drugs is necessary to anticipate potential complications. Management of acute leukemias and lymphomas arising in patients with connective tissue disorders is particularly challenging. Further data are needed to define the best treatment options and thus enrollment in clinical trials is encouraged for these patients.
George
C S
CS
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio, USA.
Lichtin
A E
AE
D000740:Anemia / Q000139:chemically induced / Q000628:therapy; D018501:Antirheumatic Agents / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D016867:Immunocompromised Host; D007938:Leukemia / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced / Q000628:therapy; D008223:Lymphoma / Q000139:chemically induced; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D018501:Antirheumatic Agents